The Multi-Cancer Early Detection Screening Coverage Act would ensure prompt access to FDA-approved multi-cancer screening tests and fuel innovation in cancer screening
This is a bill to prove 5% real funding increases to National Institutes of Health (NIH), Centers for Disease Control (CDC), Department of Defense (DoD) medical research, and Department of Veterans Affairs (VA) medical research for each of the next ten fiscal years.
This bill is the Promoting Resources to Expand Vaccination, Education and New Treatments for HPV Cancers Act or the PREVENT HPV Cancers Act with the ultimate goal of preventing HPV-related cancers.
This bill would authorize appropriations for offsetting the costs related to reductions in research productivity resulting from the coronavirus pandemic.
This bill would provide temporary licensing reciprocity for telehealth and interstate health care treatment during national emergencies.
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a group health plan or a health insurance issuer.
This bill includes certain lymphedema compression treatment items as covered durable medical equipment under Medicare. (Lymphedema is a condition of localized fluid retention and tissue swelling that is caused when the lymphatic system is damaged or blocked.)
This bill waives Medicare coinsurance requirements with respect to colorectal cancer screening tests, regardless of the code billed for a resulting diagnosis or procedure, was signed into law as a provision in the FY2021 budget and COVID-19 response legislation, in section 122. Fight Colorectal Cancer provides a nice summary of the bill's history.
This bill, which requires state Medicaid programs to cover routine patient costs for items and services that are provided in connection with a qualifying clinical trial regarding cancer or other life-threatening conditions, was signed into law on December 27, 2020 as a part of H.R.133 - Consolidated Appropriations Act, 2021.